Revenue
240 million USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 240335000 USD Source
Fundies. English
TG Therapeutics, Inc.
EDGARAnnual consolidated revenue for 2025: about USD 616.3M, using the latest reported figures. The previous period, 2024, was about USD 329M.
Latest quarter
Operating margin
9.02%
2026 Q2 · %
Operating cash flow
39.3 million USD
2026 Q2 · USD
Free cash flow
39 million USD
2026 Q2 · USD
- Cash and cash equivalents
- 483 million USD Source
Exact value
482575000 USD
- Long-term debt including current maturities
- 100 million USD Source
Exact value
100403000 USD
- Shares outstanding
- 153 million shares Source
Exact value
153077784 shares
Reported share-count change
-3.13% · -4.95 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
800 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Net income
441 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Operating cash flow
17.9 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -44432000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -21279000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -24772000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -44432000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -17894000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: 21369000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -17894000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
491 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Capital expenditure: 147000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 67000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 214000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 147000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 51000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 344000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 51000 USD · 2026-01-01 – 2026-03-31 Source
Free cash flow
17.4 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -44432000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -21279000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -24772000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -44432000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -17894000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: 21369000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -17894000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 147000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 67000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 214000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 147000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 51000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 344000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 51000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-05.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 8 of 11 periods available· newest 2025-12-31
- Operating income: 9 of 11 periods available· newest 2025-12-31
- Net income: 5 of 11 periods available· newest 2025-12-31
- Operating cash flow: 9 of 11 periods available· newest 2025-12-31
- Capital expenditure: 9 of 11 periods available· newest 2025-12-31
- Total assets: 7 of 11 periods available· newest 2025-12-31
- Total liabilities: 7 of 11 periods available· newest 2025-12-31
- Current assets: 7 of 11 periods available· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2023-12-31
- Shares outstanding: 7 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+87.3%Prior period
USD 329 million
–
Current period
USD 616.29 million
–
Exact inputs and evidence
616287000 − 329004000 = 287283000 USD
329004000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source616287000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+1,812.4%Prior period
USD 23.38 million
–
Current period
USD 447.18 million
–
Exact inputs and evidence
447179000 − 23383000 = 423796000 USD
23383000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source447179000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 15.75 millionPrior period
−USD 40.52 million
–
Current period
−USD 24.77 million
–
Exact inputs and evidence
-24772000 − -40517000 = 15745000 USD
-40517000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-24772000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+375.6%Prior period
USD 45,000
–
Current period
USD 214,000
–
Exact inputs and evidence
214000 − 45000 = 169000 USD
45000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source214000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 616.29 million 100% of revenue
- Cost of revenue USD 100.71 million 16% of revenue
- Operating expenses USD 392.25 million 64% of revenue
- Operating income USD 123.32 million 20% of revenue
- Tax, interest and other Derived −USD 323.86 million −53% of revenue
- Net income USD 447.18 million 73% of revenue
Cash
- Operating cash flow −USD 24.77 million −4% of revenue
- Capital expenditure USD 214,000 0% of revenue
- Free cash flow Derived −USD 24.99 million −4.1% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2016 Not shown: operating income or net income is not reported.
- 2017 Not shown: operating income or net income is not reported.
- 2018 Not shown: operating income or net income is not reported.
- 2021 Operating loss: operating costs were 5,254% of revenue.
- 2022 Operating loss: operating costs were 7,939% of revenue.
- 2023 91%
- 2024 87%
- 2025 Net income was higher than operating income, so the split is not drawn.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | 152000 | 79121000 Derived | -78969000 | Unavailable | Unavailable | -61931000 Derived | Source
|
| 2017 2017-01-01 – 2017-12-31 | 152000 | 118864000 Derived | -118712000 | Unavailable | Unavailable | -93762000 Derived | Source
|
| 2018 2018-01-01 – 2018-12-31 | 152000 | 174552000 Derived | -174400000 | Unavailable | Unavailable | -129015000 Derived | Source
|
| 2021 2021-01-01 – 2021-12-31 | 6689000 | 351459000 Derived | -344770000 | 3331000 Derived | -348101000 | -296035000 Derived | Source
|
| 2022 2022-01-01 – 2022-12-31 | 2785000 | 221101000 Derived | -218316000 | 5496000 Derived | -223812000 | -176184000 Derived | Source
|
| 2023 2023-01-01 – 2023-12-31 | 233662000 | 213029000 Derived | 20633000 | 7961000 Derived | 12672000 | -31413000 Derived | Source
|
| 2024 2024-01-01 – 2024-12-31 | 329004000 | 287075000 Derived | 41929000 | 18546000 Derived | 23383000 | -40562000 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 616287000 | 492963000 Derived | 123324000 | -323855000 Derived | 447179000 | -24986000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 616.3M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Revenue | 152000 |
|
| 2017 | Revenue | 152000 |
|
| 2018 | Revenue | 152000 |
|
| 2021 | Revenue | 6689000 |
|
| 2022 | Revenue | 2785000 |
|
| 2023 | Revenue | 233662000 |
|
| 2024 | Revenue | 329004000 |
|
| 2025 | Revenue | 616287000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
87.3% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Year over year | No prior comparable period |
|
| 2017 | Year over year | 0% |
|
| 2018 | Year over year | 0% |
|
| 2021 | Year over year | No prior comparable period |
|
| 2022 | Year over year | -58.4% |
|
| 2023 | Year over year | 8,290% |
|
| 2024 | Year over year | 40.8% |
|
| 2025 | Year over year | 87.3% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin 20% 2025
Net margin 72.6% 2025
Free cash flow margin -4.1% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Operating margin | -51,953.3% |
|
| 2017 | Operating margin | -78,100% |
|
| 2018 | Operating margin | -114,736.8% |
|
| 2021 | Operating margin | -5,154.3% |
|
| 2022 | Operating margin | -7,839% |
|
| 2023 | Operating margin | 8.8% |
|
| 2024 | Operating margin | 12.7% |
|
| 2025 | Operating margin | 20% |
|
| 2016-12-31 | Net margin | Not reported |
|
| 2017-12-31 | Net margin | Not reported |
|
| 2018-12-31 | Net margin | Not reported |
|
| 2021 | Net margin | -5,204.1% |
|
| 2022 | Net margin | -8,036.3% |
|
| 2023 | Net margin | 5.4% |
|
| 2024 | Net margin | 7.1% |
|
| 2025 | Net margin | 72.6% |
|
| 2016 | Free cash flow margin | -40,744.1% |
|
| 2017 | Free cash flow margin | -61,685.5% |
|
| 2018 | Free cash flow margin | -84,878.3% |
|
| 2021 | Free cash flow margin | -4,425.7% |
|
| 2022 | Free cash flow margin | -6,326.2% |
|
| 2023 | Free cash flow margin | -13.4% |
|
| 2024 | Free cash flow margin | -12.3% |
|
| 2025 | Free cash flow margin | -4.1% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -24.8M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Operating cash flow | -61587000 |
|
| 2017 | Operating cash flow | -93760000 |
|
| 2018 | Operating cash flow | -128925000 |
|
| 2021 | Operating cash flow | -295634000 |
|
| 2022 | Operating cash flow | -176170000 |
|
| 2023 | Operating cash flow | -31413000 |
|
| 2024 | Operating cash flow | -40517000 |
|
| 2025 | Operating cash flow | -24772000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -25M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Free cash flow | -61931000 |
|
| 2017 | Free cash flow | -93762000 |
|
| 2018 | Free cash flow | -129015000 |
|
| 2021 | Free cash flow | -296035000 |
|
| 2022 | Free cash flow | -176184000 |
|
| 2023 | Free cash flow | -31413000 |
|
| 2024 | Free cash flow | -40562000 |
|
| 2025 | Free cash flow | -24986000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
39.1% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Liabilities / assets | 34.5% |
|
| 2017 | Liabilities / assets | 31.2% |
|
| 2018 | Liabilities / assets | 71.3% |
|
| 2021-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2022 | Liabilities / assets | 69.7% |
|
| 2023 | Liabilities / assets | 51.3% |
|
| 2024 | Liabilities / assets | 61.5% |
|
| 2025 | Liabilities / assets | 39.1% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
4.1× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Current assets / current liabilities | 3.01× |
|
| 2017 | Current assets / current liabilities | 3.34× |
|
| 2018 | Current assets / current liabilities | 2.03× |
|
| 2021-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2022 | Current assets / current liabilities | 3.16× |
|
| 2023 | Current assets / current liabilities | 5.92× |
|
| 2024 | Current assets / current liabilities | 6.25× |
|
| 2025 | Current assets / current liabilities | 4.1× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | Unavailable Not reported for this period. | −USD 44.69 million Exact valueExact value: -44690272 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 42,217 Exact valueExact value: 42217 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 44.73 million Calculation and evidence-44690272 − 42217 USD Exact free cash flow: -44732489 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2016 2016-01-01 – 2016-12-31 | Unavailable Not reported for this period. | −USD 61.59 million Exact valueExact value: -61587000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 344,000 Exact valueExact value: 344000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 61.93 million Calculation and evidence-61587000 − 344000 USD Exact free cash flow: -61931000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2017 2017-01-01 – 2017-12-31 | Unavailable Not reported for this period. | −USD 93.76 million Exact valueExact value: -93760000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2,000 Exact valueExact value: 2000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 93.76 million Calculation and evidence-93760000 − 2000 USD Exact free cash flow: -93762000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2018-01-01 – 2018-12-31 | Unavailable Not reported for this period. | −USD 128.93 million Exact valueExact value: -128925000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 90,000 Exact valueExact value: 90000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 129.02 million Calculation and evidence-128925000 − 90000 USD Exact free cash flow: -129015000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 348.1 million Exact valueExact value: -348101000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 295.63 million Exact valueExact value: -295634000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 401,000 Exact valueExact value: 401000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 296.04 million Calculation and evidence-295634000 − 401000 USD Exact free cash flow: -296035000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 223.81 million Exact valueExact value: -223812000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 176.17 million Exact valueExact value: -176170000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 14,000 Exact valueExact value: 14000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 176.18 million Calculation and evidence-176170000 − 14000 USD Exact free cash flow: -176184000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | USD 12.67 million Exact valueExact value: 12672000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 31.41 million Exact valueExact value: -31413000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: -0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 31.41 million Calculation and evidence-31413000 − -0 USD Exact free cash flow: -31413000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | USD 23.38 million Exact valueExact value: 23383000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 40.52 million Exact valueExact value: -40517000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 45,000 Exact valueExact value: 45000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 40.56 million Calculation and evidence-40517000 − 45000 USD Exact free cash flow: -40562000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | USD 447.18 million Exact valueExact value: 447179000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.77 million Exact valueExact value: -24772000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 214,000 Exact valueExact value: 214000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.99 million Calculation and evidence-24772000 − 214000 USD Exact free cash flow: -24986000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
157 filings · 4,751 latest values · 4,751 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001001316, 1001316, TGTX, edgar:1001316, mhan, tgtx, tgtxd
Also known as ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC, TG THERAPEUTICS, INC., TG THERAPEUTICS, INC., TG Therapeutics, Inc.